ABVC BioPharma与OncoX签署全面许可协议 - ABVC与OncoX签署了涵盖治疗非小细胞肺癌的单一草本药物提取物许可协议[1] - ABVC获得了1250万美元的里程碑付款和5%的净销售额提成，以及额外的1250万美元里程碑付款[1] ABVC授予OncoX独家权利 - ABVC授予OncoX独家权利开发、生产和商业化BLEX 404，这是一种有望用于治疗非小细胞肺癌的治疗药物[2] 合作目标 - ABVC和OncoX共同致力于推动医学科学的发展和改善患者护理，以确保BLEX 404的成功开发和商业化[3]

ABVC BioPharma, Inc.许可协议 - ABVC BioPharma, Inc.与其附属公司BioLite, Inc.和Rgene Corporation与OncoX BioPharma, Inc.签署了一项潜在的具有突破性意义的许可协议[1] - ABVC将获得5000万美元的许可费用，并在首次筹款轮后再获得500万美元的里程碑付款[2] ABVC产品管道潜力 - ABVC的产品管道在全球癌症治疗市场具有巨大潜力，预计到2032年市值将达到约3936.1亿美元[8]

FREMONT, CA, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire  – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that one of its subsidiaries, AiBtl BioPharma Inc. (AIBL), entered into an Agreement to exchange a 100% ownership stake in certain real estate for 1,533,333 shares of AIBL stock at $5 per share. The property is valued at approximately $7.6 million ba ...

FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results. These results, including the financial statements included herein, can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2024. 2023 ...

公司业务合作 - ABVC 和其子公司 BioLite, Inc. 与 AIBL 达成了一项全球许可协议，涉及 CNS 药物 MDD 和 ADHD 的授权产品[3] - 公司与 Zhonghui 达成合作协议，计划将位于中国四川乐山的地产开发为医疗中心[5] - 公司与 Senior Paradise, Inc. 签订了授权协议，将其医疗相关专业知识授权给 SPI，并租赁部分房地产物业[7] 资产收购与发行 - ABVC 收购了额外的房地产资产，希望将其用作亚洲医疗保健业务和医药生物技术行业的综合平台[6] - 公司通过直接注册发行出售了30万股普通股和20万股预先融资认股权证，募集了175万美元[9] 临床研究与合作 - 美国食品药品监督管理局（FDA）批准了针对EGFR野生型非小细胞肺癌的BLEX 404临床研究的IND申请[27] - BioKey与Rgene Corporation合作开发的治疗方案获得了台湾FDA的批准[27] - BioKey与Rgene Corporation签订了一项为期三年、价值高达300万美元的临床开发服务合同[29] 公司财务状况 - 公司已恢复符合纳斯达克市场规则，包括维持最低1.00美元的竞标价格和250万美元的最低股东权益要求[4] - ABVC 成功减少了2023年的净亏损，通过更有效地利用资金和停止某些咨询服务[17] - 公司的现金及现金等价物在2023年底为60,155美元[18] - 公司的净亏损为1.091亿美元，较上一年度有所减少[35] - 公司的营收为15.243亿美元，较上一年度有所下降[35] - 公司的现金及现金等价物和受限现金总额为716.78万美元[36] 生产与销售合作 - BioKey在加利福尼亚弗里蒙特的全资子公司，生产来自舞茸的膳食补充剂[28] - BioKey与Define Biotech Co. Ltd.签订了分销协议，计划为全球市场生产额外价值100万美元的产品[28]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40700 ABVC BioPharma, Inc. (Exact name of Company in its charter) Nevada 26-0014658 (State or other jurisdiction of (I.R.S. Employer incorporation o ...

FREMONT, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today provided an update on its development of combination therapy for the treatment of cancer and immunity booster dietary supplements. The Company is currently marketing dietary supplements, as well as continuing to pursue clinical trials of phar ...

FREMONT, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to license certain of its healthcare-related expertise ("Know-How") to Senior Paradise, Inc. ("SPI"), who will also lease certain of the Company's properties (the "Land") for further development related to the hea ...

FREMONT, CA , Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Company holds a U.S. patent for the same treatment via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received an Australian patent, valid until 2040, Application No. 2021314052, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, used in the Company's asset ABV- ...

FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC's bo ...